Wilson A G, Kung H C, Boroujerd M, Anderson M W
Cancer Res. 1981 Sep;41(9 Pt 1):3453-60.
The lungs of A/HeJ mice are susceptible to benzo(a)pyrene (BP)-induced neoplasia whereas the livers are resistant. Following p.o. administration of a carcinogenic dose of [3H]BP, radioactivity was associated with the DNA of both lung and liver. Analysis of the deoxyribonucleosides by high-pressure liquid chromatography showed that the major adduct in both tissues chromatographed as the (+/-)-7 beta, 8 alpha-dihydroxy-9 alpha, 10 alpha-epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene (BPDEI)-deoxyguanosine adduct. The (+/-)-7 beta, 8 alpha-dihydroxy-9 beta, 10 beta-epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene (BPDEII)-deoxyguanosine adduct was 9 to 15% of the BPDEI adduct in both lung and liver. Although total DNA-associated radioactivity was approximately 12-fold higher in liver than in lung, the specific activities of the BP diol-epoxide adducts were approximately the same in these organs. Treatment of animals with beta-naphthoflavone (beta NF), an inhibitor of pulmonary adenoma formation, markedly decreased the amount of the BDPEI and BPDEII adducts in the lung and the liver. The decrease in the amount of these adducts in the lung correlates with the inhibition of tumorigenesis by beta NF. The inhibition of total DNA-associated radioactivity was significantly less than the BP diol-epoxide adducts. Thus, beta NF appears to inhibit BP-induced pulmonary neoplasia by reducing the amount of the BPDEI-deoxyguanosine adduct. Other inducers of aryl hydrocarbon hydroxylase were also tested for their effect on the formation of BP-deoxyribonucleoside adducts. Both 2,3,7,8-tetrachlorodibenzo-p-dioxin and Aroclor 1254 significantly reduced the amount of the BPDEI adduct in both lung and liver. These data would suggest that both 2,3,7,8-tetrachlorodibenzo-p-dioxin and Aroclor 1254, like beta NF, should protect against BP-induced pulmonary neoplasia. The effects of aryl hydrocarbon hydroxylase inducers on the binding of BP to DNA in vivo markedly contrast with their effect in vitro. Treatment of animals with aryl hydrocarbon hydroxylase inducers stimulates the formation of BP diol-epoxide adducts in vitro. The reason for the differences between our in vivo results and those predicted from in vitro studies is unclear.
A/HeJ小鼠的肺对苯并(a)芘(BP)诱导的肿瘤形成敏感,而肝脏则具有抗性。经口给予致癌剂量的[3H]BP后,放射性与肺和肝脏的DNA相关。通过高压液相色谱对脱氧核苷进行分析表明,两种组织中的主要加合物在色谱图上表现为(+/-)-7β,8α-二羟基-9α,10α-环氧-7,8,9,10-四氢苯并(a)芘(BPDEI)-脱氧鸟苷加合物。(+/-)-7β,8α-二羟基-9β,10β-环氧-7,8,9,10-四氢苯并(a)芘(BPDEII)-脱氧鸟苷加合物在肺和肝脏中均占BPDEI加合物的9%至15%。尽管肝脏中与DNA相关的总放射性比肺中高约12倍,但这些器官中BP二醇环氧化物加合物的比活性大致相同。用β-萘黄酮(βNF)(一种肺腺瘤形成抑制剂)处理动物,可显著降低肺和肝脏中BDPEI和BPDEII加合物的量。肺中这些加合物量的减少与βNF对肿瘤发生的抑制作用相关。对总DNA相关放射性的抑制明显小于BP二醇环氧化物加合物。因此,βNF似乎通过减少BPDEI-脱氧鸟苷加合物的量来抑制BP诱导的肺肿瘤形成。还测试了其他芳烃羟化酶诱导剂对BP-脱氧核糖核苷加合物形成的影响。2,3,7,8-四氯二苯并-p-二恶英和多氯联苯混合物Aroclor 1254均显著降低了肺和肝脏中BPDEI加合物的量。这些数据表明,2,3,7,8-四氯二苯并-p-二恶英和Aroclor 1254与βNF一样,应能预防BP诱导的肺肿瘤形成。芳烃羟化酶诱导剂对BP在体内与DNA结合的影响与它们在体外的影响明显不同。用芳烃羟化酶诱导剂处理动物在体外会刺激BP二醇环氧化物加合物的形成。我们体内结果与体外研究预测结果之间存在差异的原因尚不清楚。